10-Q: Unicycive Therapeutics Reports Q3 2025, OLC NDA Resubmission

Unicycive Therapeutics reported a reduced net loss and increased cash reserves in Q3 2025, while planning to resubmit its Oxylanthanum Carbonate NDA by year-end following an FDA meeting.

Summary

• Net loss for the nine months ended September 30, 2025, decreased to $11.9 million from $15.2 million in the prior year period.
• Cash and cash equivalents increased to $42.7 million as of September 30, 2025, from $26.1 million at December 31, 2024.
• Research and development expenses significantly decreased by 53% to $6.9 million for the nine months ended September 30, 2025, compared to $14.7 million in the same period of 2024.
• General and administrative expenses increased by 90% to $15.4 million for the nine months ended September 30, 2025, from $8.1 million in the prior year period.
• The company plans to resubmit its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) by year-end 2025, addressing a single manufacturing vendor compliance deficiency identified in a June 30, 2025 Complete Response Letter (CRL).
• A 1-for-10 reverse stock split became effective on June 20, 2025.
• The company raised approximately $38.6 million in net proceeds from the sale of 8,046,736 shares of common stock through an 'at the market' offering during the nine months ended September 30, 2025.
• Subsequent to September 30, 2025, an additional $3.0 million in net proceeds was raised from the sale of 641,033 shares of common stock.

Sentiment

Score: 4

Explanation: While the net loss improved and cash reserves increased due to financing, the significant delay in OLC NDA approval due to a CRL, coupled with multiple shareholder lawsuits, creates substantial uncertainty and negative sentiment. The increased operating cash burn is also a concern.

Positives

• Net loss for the nine months ended September 30, 2025, improved to $11.9 million, down from $15.2 million in the same period of 2024.
• Cash and cash equivalents significantly increased to $42.7 million as of September 30, 2025, providing enhanced liquidity.
• The company successfully raised approximately $38.6 million in net proceeds from an 'at the market' common stock offering, with an additional $3.0 million raised post-quarter.
• The FDA's Complete Response Letter for OLC NDA identified only a single deficiency related to a third-party manufacturing vendor's compliance, with no concerns regarding pre-clinical, clinical, or safety data.
• Resubmission of the OLC NDA is planned by year-end 2025, indicating progress towards potential approval.
• The warrant liability decreased significantly from $18.9 million at December 31, 2024, to $9.1 million at September 30, 2025, reducing future obligations.
• Total stockholders' equity increased substantially to $37.5 million from $7.4 million at December 31, 2024.

Negatives

• General and administrative expenses increased significantly by 90% to $15.4 million for the nine months ended September 30, 2025.
• Net cash used in operating activities increased to $23.3 million for the nine months ended September 30, 2025, from $22.0 million in the prior year, indicating higher cash burn.
• The company received a Complete Response Letter (CRL) for its Oxylanthanum Carbonate NDA on June 30, 2025, delaying potential market entry.
• A putative shareholder class action lawsuit was filed on August 15, 2025, alleging material misrepresentations regarding OLC NDA prospects.
• Two shareholder derivative actions were filed on October 30 and November 7, 2025, alleging false statements and breach of fiduciary duty by management regarding the OLC NDA.
• The company expects to continue incurring losses and will require additional capital in the future to fund operations and clinical trials.

Risks

• The company is subject to risks and uncertainties common to early-stage biotechnology companies, including competitor innovations, proprietary technology protection, dependence on key personnel, governmental regulations, and the need for additional financing.
• Product candidates require significant additional research and development efforts prior to commercialization.
• Future revenue streams are uncertain and may consist of collaboration/licensing revenue or product sales.
• Operating losses and negative cash flows from operations are expected to continue and increase with research and development activities.
• There is no assurance that additional financing will be obtainable on acceptable terms or in a timely manner, potentially requiring curtailment of clinical trials and product development.
• The company's product candidates require FDA or other international regulatory approvals, which are not assured and could be delayed or denied, materially impacting the company.
• Substantial funds are required to complete research, development, clinical testing, commercial-scale manufacturing, marketing, and distribution, which cannot be entirely funded by current financial resources.
• The company is dependent upon the services of its employees, consultants, and other third parties.
• The company is involved in legal proceedings, including a shareholder class action and two shareholder derivative actions, which are inherently uncertain and could result in significant resource expenditure, substantial legal fees, and potential material losses.
• The outcome of pending lawsuits is uncertain, and the company may not prevail or settle within insurance coverage limits, potentially distracting management from business activities.
• The fair value estimates for warrant liabilities involve management's judgment and unobservable inputs, and actual results may differ materially from these estimates.

Future Outlook

The company expects to continue incurring losses and negative cash flows from operations as it advances product candidates through clinical development, seeks regulatory approval, and prepares for commercialization. Additional capital will be required to complete planned clinical trials, pursue product development, and penetrate markets. Management believes it has sufficient resources for at least one year but acknowledges the need for future financing through equity offerings, debt, or collaborations. The OLC NDA resubmission is planned by year-end 2025, and the company intends to pay quarterly dividends equal to at least 75% of annual net cash flow from operations following FDA approval and commercial sales of OLC.

Management Comments

• Management believes that the company has sufficient resources such that there is not substantial doubt about the ability to continue operations for at least one year after the date these financial statements are available to be issued.
• Management believes that its broad network, expertise in the biopharmaceutical industry, and successful track record gives it an advantage in identifying and bringing assets into the company at an attractive price with limited upfront cost.
• We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results or expectations, except as required by law.

Industry Context

Unicycive Therapeutics operates in the highly competitive clinical-stage biotechnology industry, focusing on kidney disease, a therapeutic area with significant unmet medical needs. The company's strategy of in-licensing and developing novel therapies like Oxylanthanum Carbonate (OLC) for hyperphosphatemia and UNI-494 for acute kidney injury aligns with broader industry trends where specialized biotech firms target orphan diseases and specific metabolic conditions. The challenges faced, such as FDA Complete Response Letters and the need for continuous capital raises, are common for early-stage biopharmaceutical companies navigating complex regulatory pathways and high development costs. The company's sublicense agreements for OLC in Asian markets demonstrate a common strategy for smaller biotechs to leverage global partners for market penetration outside their primary focus regions.

Comparison to Industry Standards

• The company's accumulated deficit of $113.2 million and continued operating losses are typical for clinical-stage biotechnology companies that require substantial investment in R&D before commercialization and revenue generation.
• The reliance on equity offerings and debt financing for funding operations is a standard practice for biotech firms without significant product revenue.
• The receipt of a Complete Response Letter (CRL) from the FDA, even for a single manufacturing deficiency, is a common regulatory hurdle in the drug approval process, similar to experiences of other pharmaceutical developers.
• The significant increase in general and administrative expenses (90%) is higher than typical for mature companies but can be expected for a growing public company expanding infrastructure and incurring increased compliance, legal, and investor relations costs.
• The successful capital raise through an 'at the market' offering demonstrates access to capital markets, which is crucial for sustaining operations in the biotech sector, comparable to other small-cap biotechs seeking to fund ongoing development.

Corporate Governance

Legal Proceedings

• On August 15, 2025, a putative shareholder class action complaint, Elkhodari v. Unicycive Therapeutics, Inc., et al., was filed in the U.S. District Court for the Northern District of California. It alleges material misrepresentations and/or omissions regarding the prospects of the OLC NDA between March 29, 2024, and June 27, 2025, seeking unspecified monetary damages and costs.
• On October 30, 2025, a shareholder derivative action, Jackson v. Gupta, et al., was filed in the U.S. District Court for the Northern District of California against certain board members and officers. It alleges they authorized or permitted materially false statements/omissions regarding the OLC NDA, seeking unspecified damages, corporate governance reforms, disgorgement, and restitution.
• On November 7, 2025, a second shareholder derivative action, Henry v. Gupta, et al., was filed in the U.S. District Court for the Northern District of California, making similar allegations and seeking similar remedies as the Jackson Action.
• The company intends to vigorously defend against these claims but is unable to predict the outcome or estimate possible losses at this early stage.

Related Party Transactions

• The company in-licensed the drug candidate UNI 494 from Sphaera Pharma Pte. Ltd., a Singapore-based corporation and a stockholder.
• The company purchased Renazorb (Oxylanthanum Carbonate) and related intellectual property from Spectrum Pharmaceuticals, Inc., which included an anti-dilution provision for Spectrum to maintain a 4% ownership interest until certain conditions were met (satisfied July 13, 2021).

Stakeholder Impact

• **Shareholders:** Face dilution from recent and potential future equity raises, significant uncertainty due to the OLC NDA delay and ongoing legal proceedings (class action and derivative lawsuits), and potential for stock price volatility.
• **Employees:** Continued employment and potential for stock-based compensation, but uncertainty from ongoing losses and the need for future capital raises could impact job security or growth opportunities.
• **Customers (future):** Potential for a new treatment option (OLC) for hyperphosphatemia in CKD patients on dialysis, but its availability is delayed due to regulatory hurdles.
• **Suppliers/Partners:** Continued engagement with contract manufacturing organizations (e.g., Shilpa Medicare Ltd.) and clinical research organizations (e.g., Quotient Sciences Limited, Inotiv) for product development and manufacturing, with potential for increased demand if OLC is approved.
• **Creditors:** The company's ability to secure additional financing and manage its cash burn will be critical for meeting future obligations.

Next Steps

• Resubmit the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) by year-end 2025.
• Engage in discussions with the third-party manufacturing vendor to resolve the compliance deficiency identified by the FDA.
• Continue to advance product candidates through pre-clinical and clinical development.
• Seek regulatory approval for product candidates.
• Prepare for and, if approved, proceed to commercialization of product candidates.
• Identify, acquire, discover, validate, and develop additional product candidates.
• Obtain, maintain, protect, and enforce intellectual property portfolio.
• Hire additional personnel to support growth and product development.
• Vigorously defend against the pending shareholder class action and derivative lawsuits.
• Raise additional capital through equity offerings, debt financings, corporate collaborations, or other means to fund future operations.

Key Dates

Recommendation

The company shows improved net loss and a strong cash position from recent capital raises, which are positive for short-term liquidity. However, the significant delay in the Oxylanthanum Carbonate (OLC) NDA approval due to a Complete Response Letter (CRL) and the subsequent filing of multiple shareholder lawsuits introduce substantial uncertainty and downside risk. While the FDA's concerns were limited to a manufacturing vendor, the legal challenges could be costly and distracting. The stock is likely to remain volatile until there is clarity on the OLC approval and resolution of the legal proceedings. A 'hold' recommendation is appropriate given the mixed signals: improved financials and progress on OLC resubmission are balanced by regulatory delays and significant legal overhangs.

Keywords

Unicycive Therapeutics, UNCY, Biotechnology, Kidney Disease, Oxylanthanum Carbonate, OLC, Hyperphosphatemia, Chronic Kidney Disease, CKD, Dialysis, UNI-494, Acute Kidney Injury, AKI, FDA, NDA, Complete Response Letter, CRL, Clinical Trials, Drug Development, SEC Filing, 10-Q, Financial Results, Shareholder Lawsuit, Capital Raise, Reverse Stock Split